ED50 of Sufentanil for Intraoperative Analgesia

Launched by CHINA INTERNATIONAL NEUROSCIENCE INSTITUTION · Oct 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called sufentanil, which is a strong pain reliever used during laparoscopic cholecystectomy, a type of surgery to remove the gallbladder. The researchers want to find out the lowest effective dose of sufentanil when combined with another medication called dexmedetomidine. This combination aims to provide enough pain relief while potentially using less of the stronger medication. They will use a specific method called the "up and down method" to determine this dosage.

To join the trial, participants need to be between 18 and 65 years old, have a body mass index (BMI) between 22 and 30, and be scheduled for the laparoscopic gallbladder surgery. However, people with certain health issues or those taking specific medications will not be eligible. If you participate, you can expect to receive careful monitoring during the surgery to ensure your comfort and safety as the researchers gather important information about the medication's effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ASA I \~ II level;
• • 2. BMI22-30kg/m2;
• • 3. Those who intend to undergo laparoscopic cholecystectomy;
• • 4. Age 18\~65 years.
• Exclusion Criteria:
• • 1. Has been allergic to the drugs used in this study;
• • 2. Patients with a history of chronic use of alcohol, smoke or other sedative drugs;
• • 3. Patients took opioids and other analgesics before surgery;
• • 4. Emergency operation;
• • 5. Stress, anxiety resulting in secretion of catecholamine;
• • 6. Patients with neuropsychiatric disorders, coma, depression, cognitive impairment and Alzheimer's disease;
• • 7. Patients with epilepsy, autonomic nervous dysfunction and other diseases with abnormal EEG results;
• • 8. SBP\< 85 mmHg or HR\< 45次/min;
• • 9. Has implanted pacemaker;
• • 10. Patients were unwilling or disable to finish whole study;
• • 11. Patients with acute upper respiratory infections, liver or kidney failure and severe cardiopulmonary dysfunction.